Gamida completes enrolment in Phase I/II study of NiCord
The study enrolled 11 patients to evaluate NiCord as an alternative investigational treatment for HM and is expected to provide the results within six months. Gamida Cell research
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
Simponi subcutaneous injection is indicated for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Janssen Biotech discovered and developed Simponi as a treatment for inflammatory autoimmune diseases involving TNF